Cellular Dynamics International (ICEL) 16.55 $ICEL
Cellular Dynamics Appoints Derek Hei, Ph.D., as Vice President of Clinical Manufacture, Quality, and Regulatory Activities to Build Additional Capabilities for the Development and Manufacture of iPSC-Derived Cell Therapies
PR Newswire - Tue Jun 21, 11:44AM CDT
Cellular Dynamics International, Inc. (CDI), a FUJIFILM company, today announced the appointment of Derek Hei, Ph.D., as Vice President of Clinical Manufacture, Quality, and Regulatory activities to lead efforts in support of manufacturing induced pluripotent stem cell (iPSC)-based products for cell therapies. Dr. Hei has over twenty years of experience developing biotherapeutics from research through clinical trials, most recently as director at Waisman Biomanufacturing, a cGMP-compliant manufacturing facility at the University of Wisconsin-Madison.
ICEL: 16.55 (+0.03)
Cellular Dynamics Announces Partnership with The Michael J. Fox Foundation for Parkinson's Research to Provide Resources for Developing New Therapies
PR Newswire - Wed May 25, 9:00AM CDT
Cellular Dynamics International, Inc. (CDI), a FUJIFILM company, today announced an agreement with The Michael J. Fox Foundation for Parkinson's Research (MJFF) to derive induced pluripotent stem cells (iPSCs) from 85 people in the MJFF-sponsored Parkinson's Progression Markers Initiative (PPMI). The collaborators will provide the cells to the scientific community in concert with rich available clinical and imaging data on these study volunteers in service to their shared goal to provide resources to accelerate the development of new therapies.
ICEL: 16.55 (+0.03)
Global Stem Cell Banking Market 2015-2019 with Esperite, NeoStem, Smart Cells International, StemCyte & ViaCord Dominating
M2 - Wed Oct 28, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/48756j/global_stem_cell) has announced the addition of the "Global Stem Cell Banking Market 2015-2019" report to their offering. The global stem cell banking market to grow at a CAGR of 15.13% over the period 2014-2019. The report, Global Stem Cell Banking Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. The global stem cell banking market shows some growth potential because of the emergence of certain trends. One such trend is the growing awareness among the public. The adoption of this concept is growing faster in larger cities and with the upper classes who have higher disposable incomes. Stem cell transplantation services are increasing as it is necessary to create awareness among the population for the optimum utilization of these facilities. According to the report, several factors are driving the global stem cell banking market. One such factor is the rising potential for umbilical cord cell banks. Umbilical cord blood is the blood that remains in the attached umbilical cord after childbirth. This blood is a rich source of stem cells that can be used for transplants because of their ability to regenerate. Further, the report states that one of the major challenges confronting the global stem cell banking market is the huge operational costs associated with the processing and storage of stem cells. These high costs are a major challenge that is leading to a dip in the growth of the market. The report also considers the revenue generated by various segments of stem cell banks to arrive at the final market size which includes: - Applications - Products - Geography Key vendors - Esperite - NeoStem - Smart Cells International - StemCyte - ViaCord Other prominent vendors - Aldagen - Arteriocyte - Brainstorm Cell Therapeutics - Capricor - Cellartis - Cellerant Therapeutics - Cellular Dynamics International - CordCare - Cryo Stemcell - Cryo-Save India - Cytori Therapeutics - Gamida Cell - GlobalStem - International Stem Cell - Jeevan Blood Bank Research Center - Medistem - NovaCord - Reelabs - ReNeuron Group - RhinoCyte - RMS Regrow - Stemade Biotech - StemCells - StemCyte India Therapeutics - StemOne Biologicals Key Topics Covered: Part 01: Executive summary Part 02: Scope of the report Part 03: Market research methodology Part 04: Introduction Part 05: Market landscape Part 06: Market segmentation by application Part 07: Market segmentation by products Part 08: Geographical segmentation Part 09: Market drivers Part 10: Impact of drivers Part 11: Market challenges Part 12: Impact of drivers and challenges Part 13: Market trends Part 14: Vendor landscape Part 15: Key vendor analysis Part 16: Appendix For more information visit http://www.researchandmarkets.com/research/48..._stem_cell
ICEL: 16.55 (+0.03), CYTX: 2.05 (unch), BCLI: 2.39 (-0.04)
The New Age of Regenerative Medicine - Why Stem Cell Therapy?
M2 - Wed Sep 09, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/trw352/seg3d_the_new_age) has announced the addition of the "Seg3D The New Age of Regenerative Medicine" report to their offering. Cell therapy is the fastest growing segment of the Regenerative Medicine (RM) industry. It comprises both immune cell therapy and stem cell therapy; however, stem cell therapy makes up the largest part of this segment. The global cell therapy market is driven by the success of stem cell treatments in treating or curing life-threatening diseases such as cancer, heart disease, and neuro-muscular ailments among the aging population. This research study provides an overview of the regenerative medicine industry and an insight on successful stem cell therapy treatments. It also analyses marketed products, stem cell manufacturing and funding, and the collaborative partnerships in the regenerative medicine industry. Key Findings - Regenerative Medicine (RM) represents a new human-health paradigm with the potential to resolve unmet medical needs by addressing the underlying causes of diseases. - Globally, there are over companies focused on regenerative medicine. The United States has the most registered RM companies, followed by the United Kingdom, Germany and Japan. - Rapidly growing medical tourism, contract research outsourcing, and a rising population of patients with neurological and other chronic conditions are some of the factors driving the Asian stem cells market. Key Questions This Study Will Answer - What are some of the key developments impacting the regenerative medicine industry? - What are some of the key regulatory changes affecting the regenerative medicine industry? - How are investments and market consolidations progressing in Asia-Pacific? - What are some of the key participants making an impact in the regenerative medicine industry? Key Topics Covered: - Executive Summary - The New Age of Regenerative Medicine - An Overview - Stem Cell Manufacturing Facilities - Market Dynamics - Stem Cell Consumers - Future Trends - Regenerative Medicine Industry - Mergers, Acquisitions, and Partnership Assessment - Regenerative Medicine Industry - Funding Scenario - Overview of Regenerative Medicine in Asia-Pacific - Conclusion Companies Mentioned - MEDIPOST Co., Ltd. - Mesoblast Ltd. - Cellular Dynamics International (CDI) - Orthofix International - Capricor Therapeutics For more information visit http://www.researchandmarkets.com/research/tr...he_new_age
CAPR: 3.80 (+0.16), ICEL: 16.55 (+0.03)
Cellular Dynamics to Host iForum(TM) Meetings Focused on Human iPSC Research and Applications
BusinessWire - Thu Aug 13, 7:05AM CDT
Cellular Dynamics International, Inc. (CDI), a FUJIFILM company, will host the annual iForum(TM) 2015 Meeting: US on September 14-16 in Chicago, IL. With the rapidly growing interest in and use of iPSCs over recent years in drug discovery and cell therapy applications, iForum 2015 Meetings represent a natural evolution of the former CDI User Group Meetings. The iForum 2015 Meeting: Europe is slated to be held in Hamburg, Germany, on October 19.
ICEL: 16.55 (+0.03)
Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019
M2 - Thu Apr 23, 9:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z5h992/regenerative) has announced the addition of the "Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019" report to their offering. Global Regenerative Medicine market is estimated to reach US$24.7 billion by 2017. Regenerative Medicine in Orthopedics market is projected to reach US$10.3 billion by 2017, growing at a CAGR of 12.2% for the analysis period 2013-2019 respectively. Skin/Integumentary and Urology together account for approximately 25.97% (2016) of the market are expected to support the Regenerative Medicine Industry going forward. Geographical analysis for Regenerative Medicine in Cardiology shows that the highest Compounded Annual Growth Rate (CAGR) of 18.1% is anticipated from Asia-Pacific region during the analysis period 2013-2019. The report Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019' reviews the latest trends in regenerative medicine with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for healthcare sector investments. The study reveals profitable investment strategies for market start-ups, pharmaceutical/biotechnology companies, laboratories, Contract/Clinical/Commercial Research Organizations (CROs), government/academic organizations, consulting firms, database buyers and many more in preferred locations. Regenerative Medicine - Segmentation - Therapeutic Area - Orthopedics - Skin/Integumentary - Cardiology - Neurology - Urology - Other - Biological Substitutes - Cells and Biomaterials - Biomolecules - Manufacturing Factors and - Other Companies Mentioned The Americas - Cell2B (USA) - Angiocrine Bioscience (USA) - Platelet Biogenesis (USA) - Biomatrica, Inc (USA) - Athersys, Inc. (USA) - Cellular Dynamics International, Inc. (USA) - Tengion Inc (USA) - Vericel Corporation (USA) - Wright Medical Technology (USA) - Tissuegene, Inc. (USA) - Shire Regenerative Medicine (USA) - Regen Biopharma (Bio-Matrix Scientific Group) (USA) - Dsm Biomedical (USA) - Harvard Apparatus Regenerative Technology (USA) Europe - Cellserve Gmbh (Germany) - Trakcel Ltd (United Kingdom) - Crispr Therapeutics (Switzerland) Asia-Pacific - Cytori Therapeutics Inc (Japan) - Cyfuse Biomedical Kk (Japan) - Regenovo Biotechnology (China) - Cynata Therapeutics Limited (Australia) For more information visit http://www.researchandmarkets.com/research/z5...generative
VCEL: 2.25 (+0.02), ICEL: 16.55 (+0.03), CYTX: 2.05 (unch), ATHX: 1.91 (-0.03)
Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report
M2 - Tue Apr 21, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jjxlkc/complete_201516) has announced the addition of the "Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report" report to their offering. Stem cell research and experimentation have been in process for well over five decades, as stem cells have the unique ability to divide and replicate repeatedly. In addition, their unspecialized nature allows them to differentiate into a wide variety of specialized cell types. The possibilities arising from these characteristics have resulted in great commercial interest, with potential applications ranging from the use of stem cells in reversal and treatment of disease, to targeted cell therapy, tissue regeneration, pharmacological testing on cell-specific tissues, and more. Conditions such as Huntington's disease, Parkinson's disease, and spinal cord injuries are examples of clinical applications in which stem cells could offer benefits in halting or even reversing damage. Traditionally, scientists have worked with both embryonic and adult stem cells for research tools, as well as for cellular therapy. While the appeal of embryonic cells has been their ability to differentiate into any type of cell, there has been significant ethical, moral, and spiritual controversy surrounding their use. Although some adult stem cells do have differentiation capacity, it is often limited in nature, which results in fewer options for use. Thus, induced pluripotent stem cells represent a promising combination of adult and embryonic stem cell characteristics. Key Topics Covered: 1. EXECUTIVE SUMMARY 2. PURPOSE OF REPORT 3. TARGET DEMOGRAPHIC 4. SCOPE OF iPSC MARKET 5. RESEARCH METHODOLOGY 6. TECHNICAL OVERVIEW OF iPSCs 7. TIMELINE OF KEY iPSC EVENTS 8. LEVELS OF REPAIR INDUCIBLE WITH iPSCs 9. iPSC INDUSTRY CONDITIONS 10. RESEARCH APPLICATIONS FOR iPSCs 11. CHARACTERIZATION OF iPSC RESEARCH ADVANCES 12. COMPANIES SELLING iPSC RESEARCH PRODUCTS 13. iPSC RESEARCH PRODUCTS MARKET 14. COMPANIES DEVELOPING iPSC THERAPIES 15. STRATEGIC COLLABORATIONS FOR DEVELOPMENT OF iPSC PRODUCTS 16. MARKET SIZE DETERMINATIONS & PROJECTIONS 17. MARKET TREND ANALYSIS 18. MARKETING ANALYSIS: PRICE-PER-CLICK FOR iPSC-RELATED SEARCH TERMS 19. SCIENTIST PANEL: DETAILED END-USER SURVEY 20. STRATEGIES FOR ACCESSING THE iPSC MARKETPLACE 21. CONCLUSIONS Companies Mentioned - ArunA Biomedical - California Institute for Regenerative Medicine (CIRM) - CeeTox and Cellular Dynamics International (Owned by Fujifilm Holdings) - Cellular Dynamics International, Owned by FujiFilm Holdings (Industrial-Scale Production of iPSCs) - EMD Millipore - Fate Therapeutic - Kyoto University - Life Technologies, Owned by Thermo Fisher Scientific - Lonza Group AG - Ocata Therapeutics (Previously Advanced Cell Technology) - RIKEN Center - Roslin Cells, Ltd. - Sigma Aldrich - ViaCyte - iPerian For more information visit http://www.researchandmarkets.com/research/jj...ete_201516
OCAT: 8.47 (+0.01), LIFE: 2.90 (-0.05), ICEL: 16.55 (+0.03)
Great Timing For Athersys, Other Stem Cell Companies Amidst Improving Regulatory Landscape
ACCESSWIRE - Mon Apr 13, 8:35AM CDT
WHITEFISH, MT / ACCESSWIRE / April 13, 2015 / The field of regenerative medicine holds great promise for developing new treatments for notoriously difficult-to-treat diseases and conditions where small molecules, immunotherapies and other disciplines still haven't been able to deliver a safe and efficacious impact. For instance, Athersys, Inc. (NASDAQ:ATHX) is now less than two weeks away from top-line data from a Phase 2 international trial on patients suffering an ischemic stoke, an often devastating condition where there are no FDA-approved treatments beyond a four hour treatment window from time of occurrence. Mesoblast Ltd. (OTC: MBLTY)(ASX: MSB) has five product candidates based on specialized cells called mesenchymal lineage adult stem cells in, or ready for, late-stage trials targeting difficult conditions, including congestive heart failure. In a blitz of biotech deals in the waning days of March, stem cells hit the headlines with Fujifilm agreeing to acquire Cellular Dynamics International (NASDAQ: ICEL) for $307 million, a heavy 108% premium to the prior day's closing price of ICEL, to gain control of one of the aspiring leaders in the stem cell research business. This follows on the announcement in early March of the new Athersys-Chugai partnership.
ICEL: 16.55 (+0.03), TEVA: 51.22 (+0.32), ATHX: 1.91 (-0.03), MSB: 9.57 (-0.06)
Law Offices of Marc S. Henzel Announces Securities Class Action Periods
PR Newswire - Tue Apr 07, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com), a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following class periods:
NCFT: 25.50 (unch), CTRX: 61.47 (+0.04), ICEL: 16.55 (+0.03), BDBD: 11.03 (+0.04), ASPX: 100.96 (unch), HPTX: 45.99 (+0.02)
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Cellular Dynamics International, Inc. And Encourages Investors To Contact The Firm For Additional Information
BusinessWire - Mon Apr 06, 5:50PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Cellular Dynamics International, Inc. ("Cellular Dynamics" or the "Company"
(Nasdaq: ICEL) relating to the proposed buyout of the Company by FUJIFILM Holdings Corporation.
ICEL: 16.55 (+0.03)
CELLULAR DYNAMICS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Cellular Dynamics International, Inc. Over the Proposed Sale of the Company to Fujifilm Holdings Corp. - ICEL
PR Newswire - Fri Apr 03, 4:30PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Cellular Dynamics International, Inc. ("CDI" or the "Company" (NasdaqGM: ICEL) for potential breaches of fiduciary duties in connection with the sale of the Company to Fujifilm Holdings Corp. ("Fujifilm" (TYO: 4901) for approximately $307 million. The Company's stockholders will receive $16.50 for each share of CDI common stock they own.
ICEL: 16.55 (+0.03)
WeissLaw LLP: The Cellular Dynamics International Acquisition by FUJIFILM Holdings Corporation Is the Subject of a Legal Investigation
PR Newswire - Fri Apr 03, 10:41AM CDT
The fairness of the proposed acquisition of Cellular Dynamics International ("ICEL" or the "Company" by FUJIFILM Holdings Corporation ("FUJIFILM" is being investigated by WeissLaw LLP, a national class action, shareholder rights law firm. The investigation focuses on possible breaches of fiduciary duty and other violations of law by the Board of Directors of ICEL for agreeing to sell the Company to FUJIFILM. On March 30, 2015, the Company announced a definitive agreement for FUJIFILM to acquire ICEL in a transaction valued at approximately $307 million. Under the terms of the agreement, ICEL shareholders will receive $16.50 in cash for each ICEL share they own.
ICEL: 16.55 (+0.03)
EQUITY ALERT: The Rosen Law Firm Announces Investigation of Cellular Dynamics International, Inc. Concerning its Proposed Sale to Fujifilm Holdings Corporation - ICEL
BusinessWire - Wed Apr 01, 6:19PM CDT
The Rosen Law Firm, P.A., a global investor rights law firm, announces that it is investigating the Board of Directors of Cellular Dynamics International, Inc. (NASDAQ:ICEL) for possible breaches of fiduciary duty and other violations of law by failing to adequately shop Cellular Dynamics to maximize shareholder value before agreeing to be acquired by Fujifilm Holdings Corporation.
ICEL: 16.55 (+0.03)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Cellular Dynamics International, Inc.
BusinessWire - Wed Apr 01, 6:05PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cellular Dynamics International, Inc. ("Cellular Dynamics" or "the Company" (Nasdaq: ICEL) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to FUJIFILM Holdings Corporation. ("FUJIFILM" .
ICEL: 16.55 (+0.03)
WeissLaw LLP: Cellular Dynamics International Acquisition By FUJIFILM Holdings Corporation May Not Be In The Best Interest of ICEL Shareholders
PR Newswire - Wed Apr 01, 12:05PM CDT
The fairness of the proposed acquisition of Cellular Dynamics International ("ICEL" or the "Company" by FUJIFILM Holdings Corporation ("FUJIFILM" is being investigated by WeissLaw LLP, a national class action, shareholder rights law firm. The investigation focuses on possible breaches of fiduciary duty and other violations of law by the Board of Directors of ICEL for agreeing to sell the Company to FUJIFILM. On March 30, 2015, the Company announced a definitive agreement for FUJIFILM to acquire ICEL in a transaction valued at approximately $307 million. Under the terms of the agreement, ICEL shareholders will receive $16.50 in cash for each ICEL share they own.
ICEL: 16.55 (+0.03)
Ryan & Maniskas, LLP Announces Investigation of Cellular Dynamics International, Inc.
PR Newswire - Wed Apr 01, 9:43AM CDT
Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Cellular Dynamics International, Inc. ("Cellular Dynamics" or the "Company" (NASDAQ: ICEL) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to FUJIFILM Holdings Corporation in a transaction valued at approximately $307 million.
ICEL: 16.55 (+0.03)
Nasdaq stocks posting largest volume increases
AP - Tue Mar 31, 4:58PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
CFBK: 1.38 (unch), ASMI: 35.80 (-2.25), CTRX: 61.47 (+0.04), ICEL: 16.55 (+0.03), OFLX: 37.94 (-0.54), TGLS: 12.60 (-0.01), ASPX: 100.96 (unch), CCT.TO: 80.18 (+0.12), HPTX: 45.99 (+0.02)
Nasdaq stocks posting largest percentage increases
AP - Tue Mar 31, 4:58PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ADXS: 11.52 (-0.26), CTRX: 61.47 (+0.04), PACB: 8.28 (-0.02), ICEL: 16.55 (+0.03), ALIM: 1.50 (-0.05), MARPS: 3.69 (-0.06), ATRA: 19.70 (-0.15), ASPX: 100.96 (unch), CCT.TO: 80.18 (+0.12), JAXB: 16.45 (+0.40), OFIX: 45.39 (-0.13), CNCE: 9.68 (-0.03)
Cellular Dynamics Appoints Derek Hei, Ph.D., as Vice President of Clinical Manufacture, Quality, and Regulatory Activities to Build Additional Capabilities for the Development and Manufacture of iPSC-Derived Cell Therapies
PR Newswire - Tue Jun 21, 11:44AM CDT
Cellular Dynamics International, Inc. (CDI), a FUJIFILM company, today announced the appointment of Derek Hei, Ph.D., as Vice President of Clinical Manufacture, Quality, and Regulatory activities to lead efforts in support of manufacturing induced pluripotent stem cell (iPSC)-based products for cell therapies. Dr. Hei has over twenty years of experience developing biotherapeutics from research through clinical trials, most recently as director at Waisman Biomanufacturing, a cGMP-compliant manufacturing facility at the University of Wisconsin-Madison.
ICEL: 16.55 (+0.03)
Cellular Dynamics Announces Partnership with The Michael J. Fox Foundation for Parkinson's Research to Provide Resources for Developing New Therapies
PR Newswire - Wed May 25, 9:00AM CDT
Cellular Dynamics International, Inc. (CDI), a FUJIFILM company, today announced an agreement with The Michael J. Fox Foundation for Parkinson's Research (MJFF) to derive induced pluripotent stem cells (iPSCs) from 85 people in the MJFF-sponsored Parkinson's Progression Markers Initiative (PPMI). The collaborators will provide the cells to the scientific community in concert with rich available clinical and imaging data on these study volunteers in service to their shared goal to provide resources to accelerate the development of new therapies.
ICEL: 16.55 (+0.03)
Global Stem Cell Banking Market 2015-2019 with Esperite, NeoStem, Smart Cells International, StemCyte & ViaCord Dominating
M2 - Wed Oct 28, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/48756j/global_stem_cell) has announced the addition of the "Global Stem Cell Banking Market 2015-2019" report to their offering. The global stem cell banking market to grow at a CAGR of 15.13% over the period 2014-2019. The report, Global Stem Cell Banking Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. The global stem cell banking market shows some growth potential because of the emergence of certain trends. One such trend is the growing awareness among the public. The adoption of this concept is growing faster in larger cities and with the upper classes who have higher disposable incomes. Stem cell transplantation services are increasing as it is necessary to create awareness among the population for the optimum utilization of these facilities. According to the report, several factors are driving the global stem cell banking market. One such factor is the rising potential for umbilical cord cell banks. Umbilical cord blood is the blood that remains in the attached umbilical cord after childbirth. This blood is a rich source of stem cells that can be used for transplants because of their ability to regenerate. Further, the report states that one of the major challenges confronting the global stem cell banking market is the huge operational costs associated with the processing and storage of stem cells. These high costs are a major challenge that is leading to a dip in the growth of the market. The report also considers the revenue generated by various segments of stem cell banks to arrive at the final market size which includes: - Applications - Products - Geography Key vendors - Esperite - NeoStem - Smart Cells International - StemCyte - ViaCord Other prominent vendors - Aldagen - Arteriocyte - Brainstorm Cell Therapeutics - Capricor - Cellartis - Cellerant Therapeutics - Cellular Dynamics International - CordCare - Cryo Stemcell - Cryo-Save India - Cytori Therapeutics - Gamida Cell - GlobalStem - International Stem Cell - Jeevan Blood Bank Research Center - Medistem - NovaCord - Reelabs - ReNeuron Group - RhinoCyte - RMS Regrow - Stemade Biotech - StemCells - StemCyte India Therapeutics - StemOne Biologicals Key Topics Covered: Part 01: Executive summary Part 02: Scope of the report Part 03: Market research methodology Part 04: Introduction Part 05: Market landscape Part 06: Market segmentation by application Part 07: Market segmentation by products Part 08: Geographical segmentation Part 09: Market drivers Part 10: Impact of drivers Part 11: Market challenges Part 12: Impact of drivers and challenges Part 13: Market trends Part 14: Vendor landscape Part 15: Key vendor analysis Part 16: Appendix For more information visit http://www.researchandmarkets.com/research/48..._stem_cell
ICEL: 16.55 (+0.03), CYTX: 2.05 (unch), BCLI: 2.39 (-0.04)
The New Age of Regenerative Medicine - Why Stem Cell Therapy?
M2 - Wed Sep 09, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/trw352/seg3d_the_new_age) has announced the addition of the "Seg3D The New Age of Regenerative Medicine" report to their offering. Cell therapy is the fastest growing segment of the Regenerative Medicine (RM) industry. It comprises both immune cell therapy and stem cell therapy; however, stem cell therapy makes up the largest part of this segment. The global cell therapy market is driven by the success of stem cell treatments in treating or curing life-threatening diseases such as cancer, heart disease, and neuro-muscular ailments among the aging population. This research study provides an overview of the regenerative medicine industry and an insight on successful stem cell therapy treatments. It also analyses marketed products, stem cell manufacturing and funding, and the collaborative partnerships in the regenerative medicine industry. Key Findings - Regenerative Medicine (RM) represents a new human-health paradigm with the potential to resolve unmet medical needs by addressing the underlying causes of diseases. - Globally, there are over companies focused on regenerative medicine. The United States has the most registered RM companies, followed by the United Kingdom, Germany and Japan. - Rapidly growing medical tourism, contract research outsourcing, and a rising population of patients with neurological and other chronic conditions are some of the factors driving the Asian stem cells market. Key Questions This Study Will Answer - What are some of the key developments impacting the regenerative medicine industry? - What are some of the key regulatory changes affecting the regenerative medicine industry? - How are investments and market consolidations progressing in Asia-Pacific? - What are some of the key participants making an impact in the regenerative medicine industry? Key Topics Covered: - Executive Summary - The New Age of Regenerative Medicine - An Overview - Stem Cell Manufacturing Facilities - Market Dynamics - Stem Cell Consumers - Future Trends - Regenerative Medicine Industry - Mergers, Acquisitions, and Partnership Assessment - Regenerative Medicine Industry - Funding Scenario - Overview of Regenerative Medicine in Asia-Pacific - Conclusion Companies Mentioned - MEDIPOST Co., Ltd. - Mesoblast Ltd. - Cellular Dynamics International (CDI) - Orthofix International - Capricor Therapeutics For more information visit http://www.researchandmarkets.com/research/tr...he_new_age
CAPR: 3.80 (+0.16), ICEL: 16.55 (+0.03)
Cellular Dynamics to Host iForum(TM) Meetings Focused on Human iPSC Research and Applications
BusinessWire - Thu Aug 13, 7:05AM CDT
Cellular Dynamics International, Inc. (CDI), a FUJIFILM company, will host the annual iForum(TM) 2015 Meeting: US on September 14-16 in Chicago, IL. With the rapidly growing interest in and use of iPSCs over recent years in drug discovery and cell therapy applications, iForum 2015 Meetings represent a natural evolution of the former CDI User Group Meetings. The iForum 2015 Meeting: Europe is slated to be held in Hamburg, Germany, on October 19.
ICEL: 16.55 (+0.03)
Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019
M2 - Thu Apr 23, 9:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z5h992/regenerative) has announced the addition of the "Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019" report to their offering. Global Regenerative Medicine market is estimated to reach US$24.7 billion by 2017. Regenerative Medicine in Orthopedics market is projected to reach US$10.3 billion by 2017, growing at a CAGR of 12.2% for the analysis period 2013-2019 respectively. Skin/Integumentary and Urology together account for approximately 25.97% (2016) of the market are expected to support the Regenerative Medicine Industry going forward. Geographical analysis for Regenerative Medicine in Cardiology shows that the highest Compounded Annual Growth Rate (CAGR) of 18.1% is anticipated from Asia-Pacific region during the analysis period 2013-2019. The report Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019' reviews the latest trends in regenerative medicine with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for healthcare sector investments. The study reveals profitable investment strategies for market start-ups, pharmaceutical/biotechnology companies, laboratories, Contract/Clinical/Commercial Research Organizations (CROs), government/academic organizations, consulting firms, database buyers and many more in preferred locations. Regenerative Medicine - Segmentation - Therapeutic Area - Orthopedics - Skin/Integumentary - Cardiology - Neurology - Urology - Other - Biological Substitutes - Cells and Biomaterials - Biomolecules - Manufacturing Factors and - Other Companies Mentioned The Americas - Cell2B (USA) - Angiocrine Bioscience (USA) - Platelet Biogenesis (USA) - Biomatrica, Inc (USA) - Athersys, Inc. (USA) - Cellular Dynamics International, Inc. (USA) - Tengion Inc (USA) - Vericel Corporation (USA) - Wright Medical Technology (USA) - Tissuegene, Inc. (USA) - Shire Regenerative Medicine (USA) - Regen Biopharma (Bio-Matrix Scientific Group) (USA) - Dsm Biomedical (USA) - Harvard Apparatus Regenerative Technology (USA) Europe - Cellserve Gmbh (Germany) - Trakcel Ltd (United Kingdom) - Crispr Therapeutics (Switzerland) Asia-Pacific - Cytori Therapeutics Inc (Japan) - Cyfuse Biomedical Kk (Japan) - Regenovo Biotechnology (China) - Cynata Therapeutics Limited (Australia) For more information visit http://www.researchandmarkets.com/research/z5...generative
VCEL: 2.25 (+0.02), ICEL: 16.55 (+0.03), CYTX: 2.05 (unch), ATHX: 1.91 (-0.03)
Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report
M2 - Tue Apr 21, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jjxlkc/complete_201516) has announced the addition of the "Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report" report to their offering. Stem cell research and experimentation have been in process for well over five decades, as stem cells have the unique ability to divide and replicate repeatedly. In addition, their unspecialized nature allows them to differentiate into a wide variety of specialized cell types. The possibilities arising from these characteristics have resulted in great commercial interest, with potential applications ranging from the use of stem cells in reversal and treatment of disease, to targeted cell therapy, tissue regeneration, pharmacological testing on cell-specific tissues, and more. Conditions such as Huntington's disease, Parkinson's disease, and spinal cord injuries are examples of clinical applications in which stem cells could offer benefits in halting or even reversing damage. Traditionally, scientists have worked with both embryonic and adult stem cells for research tools, as well as for cellular therapy. While the appeal of embryonic cells has been their ability to differentiate into any type of cell, there has been significant ethical, moral, and spiritual controversy surrounding their use. Although some adult stem cells do have differentiation capacity, it is often limited in nature, which results in fewer options for use. Thus, induced pluripotent stem cells represent a promising combination of adult and embryonic stem cell characteristics. Key Topics Covered: 1. EXECUTIVE SUMMARY 2. PURPOSE OF REPORT 3. TARGET DEMOGRAPHIC 4. SCOPE OF iPSC MARKET 5. RESEARCH METHODOLOGY 6. TECHNICAL OVERVIEW OF iPSCs 7. TIMELINE OF KEY iPSC EVENTS 8. LEVELS OF REPAIR INDUCIBLE WITH iPSCs 9. iPSC INDUSTRY CONDITIONS 10. RESEARCH APPLICATIONS FOR iPSCs 11. CHARACTERIZATION OF iPSC RESEARCH ADVANCES 12. COMPANIES SELLING iPSC RESEARCH PRODUCTS 13. iPSC RESEARCH PRODUCTS MARKET 14. COMPANIES DEVELOPING iPSC THERAPIES 15. STRATEGIC COLLABORATIONS FOR DEVELOPMENT OF iPSC PRODUCTS 16. MARKET SIZE DETERMINATIONS & PROJECTIONS 17. MARKET TREND ANALYSIS 18. MARKETING ANALYSIS: PRICE-PER-CLICK FOR iPSC-RELATED SEARCH TERMS 19. SCIENTIST PANEL: DETAILED END-USER SURVEY 20. STRATEGIES FOR ACCESSING THE iPSC MARKETPLACE 21. CONCLUSIONS Companies Mentioned - ArunA Biomedical - California Institute for Regenerative Medicine (CIRM) - CeeTox and Cellular Dynamics International (Owned by Fujifilm Holdings) - Cellular Dynamics International, Owned by FujiFilm Holdings (Industrial-Scale Production of iPSCs) - EMD Millipore - Fate Therapeutic - Kyoto University - Life Technologies, Owned by Thermo Fisher Scientific - Lonza Group AG - Ocata Therapeutics (Previously Advanced Cell Technology) - RIKEN Center - Roslin Cells, Ltd. - Sigma Aldrich - ViaCyte - iPerian For more information visit http://www.researchandmarkets.com/research/jj...ete_201516
OCAT: 8.47 (+0.01), LIFE: 2.90 (-0.05), ICEL: 16.55 (+0.03)
Great Timing For Athersys, Other Stem Cell Companies Amidst Improving Regulatory Landscape
ACCESSWIRE - Mon Apr 13, 8:35AM CDT
WHITEFISH, MT / ACCESSWIRE / April 13, 2015 / The field of regenerative medicine holds great promise for developing new treatments for notoriously difficult-to-treat diseases and conditions where small molecules, immunotherapies and other disciplines still haven't been able to deliver a safe and efficacious impact. For instance, Athersys, Inc. (NASDAQ:ATHX) is now less than two weeks away from top-line data from a Phase 2 international trial on patients suffering an ischemic stoke, an often devastating condition where there are no FDA-approved treatments beyond a four hour treatment window from time of occurrence. Mesoblast Ltd. (OTC: MBLTY)(ASX: MSB) has five product candidates based on specialized cells called mesenchymal lineage adult stem cells in, or ready for, late-stage trials targeting difficult conditions, including congestive heart failure. In a blitz of biotech deals in the waning days of March, stem cells hit the headlines with Fujifilm agreeing to acquire Cellular Dynamics International (NASDAQ: ICEL) for $307 million, a heavy 108% premium to the prior day's closing price of ICEL, to gain control of one of the aspiring leaders in the stem cell research business. This follows on the announcement in early March of the new Athersys-Chugai partnership.
ICEL: 16.55 (+0.03), TEVA: 51.22 (+0.32), ATHX: 1.91 (-0.03), MSB: 9.57 (-0.06)
Law Offices of Marc S. Henzel Announces Securities Class Action Periods
PR Newswire - Tue Apr 07, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com), a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following class periods:
NCFT: 25.50 (unch), CTRX: 61.47 (+0.04), ICEL: 16.55 (+0.03), BDBD: 11.03 (+0.04), ASPX: 100.96 (unch), HPTX: 45.99 (+0.02)
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Cellular Dynamics International, Inc. And Encourages Investors To Contact The Firm For Additional Information
BusinessWire - Mon Apr 06, 5:50PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Cellular Dynamics International, Inc. ("Cellular Dynamics" or the "Company"
(Nasdaq: ICEL) relating to the proposed buyout of the Company by FUJIFILM Holdings Corporation. ICEL: 16.55 (+0.03)
CELLULAR DYNAMICS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Cellular Dynamics International, Inc. Over the Proposed Sale of the Company to Fujifilm Holdings Corp. - ICEL
PR Newswire - Fri Apr 03, 4:30PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Cellular Dynamics International, Inc. ("CDI" or the "Company"
(NasdaqGM: ICEL) for potential breaches of fiduciary duties in connection with the sale of the Company to Fujifilm Holdings Corp. ("Fujifilm" (TYO: 4901) for approximately $307 million. The Company's stockholders will receive $16.50 for each share of CDI common stock they own. ICEL: 16.55 (+0.03)
WeissLaw LLP: The Cellular Dynamics International Acquisition by FUJIFILM Holdings Corporation Is the Subject of a Legal Investigation
PR Newswire - Fri Apr 03, 10:41AM CDT
The fairness of the proposed acquisition of Cellular Dynamics International ("ICEL" or the "Company"
by FUJIFILM Holdings Corporation ("FUJIFILM" is being investigated by WeissLaw LLP, a national class action, shareholder rights law firm. The investigation focuses on possible breaches of fiduciary duty and other violations of law by the Board of Directors of ICEL for agreeing to sell the Company to FUJIFILM. On March 30, 2015, the Company announced a definitive agreement for FUJIFILM to acquire ICEL in a transaction valued at approximately $307 million. Under the terms of the agreement, ICEL shareholders will receive $16.50 in cash for each ICEL share they own. ICEL: 16.55 (+0.03)
EQUITY ALERT: The Rosen Law Firm Announces Investigation of Cellular Dynamics International, Inc. Concerning its Proposed Sale to Fujifilm Holdings Corporation - ICEL
BusinessWire - Wed Apr 01, 6:19PM CDT
The Rosen Law Firm, P.A., a global investor rights law firm, announces that it is investigating the Board of Directors of Cellular Dynamics International, Inc. (NASDAQ:ICEL) for possible breaches of fiduciary duty and other violations of law by failing to adequately shop Cellular Dynamics to maximize shareholder value before agreeing to be acquired by Fujifilm Holdings Corporation.
ICEL: 16.55 (+0.03)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Cellular Dynamics International, Inc.
BusinessWire - Wed Apr 01, 6:05PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cellular Dynamics International, Inc. ("Cellular Dynamics" or "the Company"
(Nasdaq: ICEL) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to FUJIFILM Holdings Corporation. ("FUJIFILM" . ICEL: 16.55 (+0.03)
WeissLaw LLP: Cellular Dynamics International Acquisition By FUJIFILM Holdings Corporation May Not Be In The Best Interest of ICEL Shareholders
PR Newswire - Wed Apr 01, 12:05PM CDT
The fairness of the proposed acquisition of Cellular Dynamics International ("ICEL" or the "Company"
by FUJIFILM Holdings Corporation ("FUJIFILM" is being investigated by WeissLaw LLP, a national class action, shareholder rights law firm. The investigation focuses on possible breaches of fiduciary duty and other violations of law by the Board of Directors of ICEL for agreeing to sell the Company to FUJIFILM. On March 30, 2015, the Company announced a definitive agreement for FUJIFILM to acquire ICEL in a transaction valued at approximately $307 million. Under the terms of the agreement, ICEL shareholders will receive $16.50 in cash for each ICEL share they own. ICEL: 16.55 (+0.03)
Ryan & Maniskas, LLP Announces Investigation of Cellular Dynamics International, Inc.
PR Newswire - Wed Apr 01, 9:43AM CDT
Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Cellular Dynamics International, Inc. ("Cellular Dynamics" or the "Company"
(NASDAQ: ICEL) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to FUJIFILM Holdings Corporation in a transaction valued at approximately $307 million. ICEL: 16.55 (+0.03)
Nasdaq stocks posting largest volume increases
AP - Tue Mar 31, 4:58PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
CFBK: 1.38 (unch), ASMI: 35.80 (-2.25), CTRX: 61.47 (+0.04), ICEL: 16.55 (+0.03), OFLX: 37.94 (-0.54), TGLS: 12.60 (-0.01), ASPX: 100.96 (unch), CCT.TO: 80.18 (+0.12), HPTX: 45.99 (+0.02)
Nasdaq stocks posting largest percentage increases
AP - Tue Mar 31, 4:58PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ADXS: 11.52 (-0.26), CTRX: 61.47 (+0.04), PACB: 8.28 (-0.02), ICEL: 16.55 (+0.03), ALIM: 1.50 (-0.05), MARPS: 3.69 (-0.06), ATRA: 19.70 (-0.15), ASPX: 100.96 (unch), CCT.TO: 80.18 (+0.12), JAXB: 16.45 (+0.40), OFIX: 45.39 (-0.13), CNCE: 9.68 (-0.03)
